Hostname: page-component-76d6cb85b7-rxvq6 Total loading time: 0 Render date: 2026-07-17T04:35:51.863Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Ramaswamy et al. “A National Modified Delphi Consensus on the Referral and Management of NF1 Plexiform Neurofibroma”

Published online by Cambridge University Press:  07 October 2025

Daniel Picard  and
Marc Remke Open the ORCID record for Marc Remke [Opens in a new window]
Daniel Picard
Affiliation:
Department of Pediatric Oncology & Haematology, Saarland University, Homburg, Germany
Marc Remke*
Affiliation:
Department of Pediatric Oncology & Haematology, Saarland University, Homburg, Germany
*
Corresponding author: Marc Remke; Email: marc.remke@uks.eu
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Ramaswamy, V, Perreault, S, Lafay-Cousin, L, Singh, D, Larner, K. A national modified Delphi consensus on the referral and management of NF1 plexiform neurofibroma. Can J Neurol Sci. 2025.10.1017/cjn.2025.10409CrossRefGoogle Scholar
Gross, AM, Dombi, E, Widemann, BC. Current status of MEK inhibitors in the treatment of plexiform neurofibromas. Childs Nerv Syst. 2020;36(10):2443–2452.10.1007/s00381-020-04731-2CrossRefGoogle ScholarPubMed
de Blank, PMK, Gross, AM, Akshintala, S, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. Neuro Oncol. 2022;24(11):1845–1856.10.1093/neuonc/noac165CrossRefGoogle ScholarPubMed
Fisher, MJ, Blakeley, JO, Weiss, BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827–1844.10.1093/neuonc/noac146CrossRefGoogle ScholarPubMed
Kerashvili, N, Gutmann, DH. The management of neurofibromatosis type 1 in children and adolescents. Expert Rev Neurother. 2024;24(4):409–420.10.1080/14737175.2024.2324117CrossRefGoogle ScholarPubMed
Legius, E, Messiaen, L, Wolkenstein, P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506–1513.10.1038/s41436-021-01170-5CrossRefGoogle ScholarPubMed